Novozymes (CPSE:NZYM B) has acquired a majority stake in Synergia Life Sciences
Synergia Life Sciences
Headquartered in Mumbai, India, Synergia is a leading producer of spore probiotics and vitamin K2-7 for the global healthcare industry. Synergia operates three production sites in India and possesses a portfolio of clinically documented spore strains for dietary food supplement and functional food applications. The company’s flagship vitamin K2-7 brand, MenaquinGold, is offered alongside a differentiated product portfolio of microbiome therapeutics, probiotics and enzymes.
By acquiring Synergia, Novozymes strengthens and accelerates its position in human health and functional foods, adding strong developing and manufacturing capabilities in spore probiotics. The Synergia product portfolio further enables and supports growth in Novozymes’ BioHealth platform. The acquisition offers a scientifically proven portfolio that strengthens Novozymes’ human health business and accelerates its functional food offerings while vertically integrating its supply chain with a key supplier. View the press release here.
Gaurav Marathe, Managing Director and Chief Executive Officer of Lincoln India, stated, “Human health and functional foods is a growing area of expertise for Lincoln. We were pleased to be able to partner with Novozymes in support of this transaction, which had a high level of complexity and required speed in execution and seamless coordination to achieve the desired outcome. Novozymes’ long-term strategy for its BioHealth platform will find a very complementary asset in Synergia, which will help further the business globally.” Tony Crisman, Managing Director in Lincoln’s Healthcare Group, added, “This transaction showcases Lincoln’s integrated global capabilities to support market leaders, such as Novozymes OneHealth with their critical, cross-border, strategic acquisition initiatives.”
Headquartered in Bagsværd, Denmark, Novozymes is a global leader in biological solutions and the world’s largest provider of enzyme and microbial technologies. Novozymes’ BioHealth platform leverages the company’s strong scientific capabilities and ability to combine microbes, pre- and probiotics, with enzymes and other biological solutions to develop innovative, effective and clinically proven solutions that improve human health and create better lives in a growing world. To learn more, please visit www.novozymes.com.
Meet our Senior Team
View More Transactions in Healthcare
Lincoln International advised Proclinic Group, a portfolio company of Miura Partners, on the acquisition of Meditrans
Lincoln International advised Frazier Lifesciences Acquisition Corporation on merger with NewAmsterdam Pharma Holding
Lincoln International advised Pfingsten Partners on the sale of Full Spectrum Group to CBRE Group
Lincoln International advised Rarebreed, a portfolio company of Trilantic Capital Partners and Halle Capital Management, on receiving significant investment from Revelstoke Capital Partners
Lincoln International advised Corus a portfolio company of Careventures and Quadrum Capital on the refinancing and acquisition of Nordentic
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.